proof of concept trials

ARENSIA delivers high degree of scientific and logistical expertise for Phase I/Ib/IIa and PROOF OF CONCEPT patient studies.




ARENSIA has contributed to numerous research projects with innovative compounds enrolling more than 1,500 COVID-19 patients.



regulatory process

ARENSIA has the know-how to successfully manage the regulatory process in various Eastern European countries.



ARENSIA locations in Eastern Europe are designed to serve patients’ medical prosperity. We are committed to enabling patients the access to new therapies as early as possible. Patient´s safety and comfort are of paramount importance at all ARENSIA´s clinics.

The healthcare systems in Eastern Europe are highly centralized with well-documented patient files.

ARENSIA’s research clinics are strategically located in the following cities: Bucharest (capital) and Cluj-Napoca (2nd largest city) in Romania, Chisinau (capital) in Moldova, Tbilisi (capital) in Georgia, Kyiv (capital) in Ukraine and Sofia (capital) in Bulgaria. These placements ensure the largest catchment areas for patients by involving the hospital departments of each clinic. We are also able to increase patient recruitment through collaborations with other hospitals/clinics in the vicinity of each unit.

At our research clinics we recruit patients through the following channels:

  • Hospital patient databases where our research clinics reside, belonging to the largest medical institutions in the given country and accumulating a large number of patients in one single spot
  • New patients seen by our Investigators daily
  • Direct patient referrals from a network of collaborating physicians located in neighbouring hospitals (radius of up to 200 km)

Healthy volunteers (as control groups to Phase I studies in renal/hepatic impaired patients) are identified usually through a small direct subject outreach.

Each ARENSIA clinic has a dedicated team of recruitment managers, overseeing a large network of collaborating physicians.

The success of our recruitment is guaranteed by our long-standing established relationships with our Principal Investigators and selected collaborating physicians. ARENSIA’s network is continuously expanding, allowing us to increase the range of our therapeutic area portfolio. Key areas include, but are not limited to, ONCOLOGY, IMMUNO-INFLAMMATORY, CARDIOVASCULAR, DIABETES/METABOLIC, RESPIRATORY, HEPATOLOGY, NEPHROLOGY, GASTROENTEROLOGY, INFECTIOUS DISEASES HCV/HBV/HIV, UROLOGY, DERMATOLOGY, NEUROLOGY, PSYCHIATRY, OPHTHALMOLOGY.

ARENSIA is able to deliver exceptionally rapid industry leading recruitment rates that include biological/treatment naïve patients.

The basis for reliable recruitment commitments at ARENSIA originates from a very thorough feasibility process. This process is performed by a detailed analysis of the available patient pools by our Principal Investigators and own dedicated medical teams that work closely with the network of collaborating physicians. For each trial, ARENSIA establishes a tailor-made recruitment strategy that depends on the required patient profile and design of the trial. This ensures that every trial is performed within the timelines initially estimated and agreed upon with the client.

When confirming recruitment figures to our clients we take into consideration all aspects/challenges of the protocol, experience/metrics from previous trials with the same patient population, competitive studies, holidays, internal resources (beds and staff). These recruitment rates are further analysed to create the optimal strategy to complete a given trial in a timely manner, whilst using the most appropriate research clinic or combination of clinics within ARENSIA.

Considering ARENSIA´s infrastructure and strict, thorough feasibility process, the enrolment figures we communicate to our Sponsors/partner CROs are reliable and robust. This approach ensures that every trial contracted by ARENSIA is performed within the timelines as agreed upon with the client.

ARENSIA's reputation is based on reliability. We give realistic projections that we pride ourselves on fulfilling. ARENSIA rejects a trial if our feasibility evaluation deems the design as unrealistic or if we could not efficiently recruit the desired patient population at our clinics.


We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse